贝瑞基因：子公司三代基因测序仪SequelIICNDx获得医疗器械注册证

Core Viewpoint - Berry Genomics (000710.SZ) has announced that its wholly-owned subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its third-generation sequencing instrument, Sequel?IICNDx, marking it as the world's first clinically approved third-generation sequencing platform [1] Group 1 - The Sequel?IICNDx instrument enables rapid implementation of third-generation sequencing solutions in local clinical laboratories, facilitating "multi-use" and "mixed operation" capabilities [1] - The approval of the Sequel?IICNDx is expected to reduce sample waiting times, accelerate report cycles, and enhance the quality and level of in-hospital services [1] - Berry Genomics has achieved full self-production of third-generation sequencing detection reagents and local deployment of an intelligent report interpretation system [1] Group 2 - The company provides comprehensive localized construction services for clinical processes, including sample collection and extraction, library construction, high-throughput sequencing, data analysis and interpretation, and report management [1]